Staar Surgical Partners with Joe Jonas to Introduce New EVO ICL
Staar Surgical announced its partnership with singer, songwriter, and actor, Joe Jonas, to raise awareness of its EVO Visian Implantable Collamer Lenses (EVO). EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia and astigmatism.
Mr. Jonas had myopia since childhood. Myopia is the most common vision disorder in the world and its prevalence is rapidly growing.1 Earlier this month, Mr. Jonas successfully had EVO lenses implanted and is now free from contact lenses and eyeglasses. EVO is designed to provide sharp, clear vision day and night, does not induce dry eye syndrome, and preserves the cornea.2,3,4 If desired, EVO lenses are also removable by a doctor for added peace of mind.
“I’ve been performing and touring ever since I was 15 years old with my brothers, and after long days and nights, I wished I didn’t have to worry about accidentally sleeping with my contacts in or keeping track of where I put my glasses, and to simply be able to wake up and see clearly,” Mr. Jonas said in a company news release. “After speaking with my doctor about this advanced new technology, I chose EVO as I felt like it was finally time to upgrade my vision and change how I could see the world. It was a seamless, easy procedure for me that quickly gave me sharp, clear vision day or night without inducing dry eye syndrome. The results are life-changing for me and with EVO, I now can simply wake up and go about my day.”
Starting in September 2022, Mr. Jonas will be sharing his journey with EVO in a global advertising, marketing and social media campaign. The campaign will help drive education and awareness of EVO among the millions of Americans who suffer from myopia and are looking for a proven and effective vision correction solution.
For more information about EVO Visian Implantable Collamer® Lenses, visit EVOICL.com.
| References: | ||
1) | Holden B, Frick T, Wilson D et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050 (Ophthalmology 2016;123:1036-1042). | |
2) | Martinez-Plazs E, Lopez-Miguel A, Lopez-De La Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226: 117–125. | |
3) | Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016 Jun 29;10:1209-15. | |
4) | Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012. | |
5) | Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clinical Ophthalmology 2018: 12: 2427–2438. | |